A Potential Solution for Eliminating Hypoxia As a Cause for Radioresistance

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2018 Oct 11

PMID 30301796

Citations 12

Authors

Mark W Dewhirst

Affiliations

Soon will be listed here.

Citing Articles

Novel Prodrug Strategies for the Treatment of Tuberculosis.

Kim C, Jose J, Hay M, Choi P Chem Asian J. 2024; 19(23):e202400944.

PMID: 39179514 PMC: 11613820. DOI: 10.1002/asia.202400944.

Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity.

Gao Z, Zhao Q, Xu Y, Wang L Radiat Oncol. 2023; 18(1):89.

PMID: 37226275 PMC: 10207801. DOI: 10.1186/s13014-023-02278-5.

Translating Data Science Results into Precision Oncology Decisions: A Mini Review.

Capobianco E, Dominietto M J Clin Med. 2023; 12(2).

PMID: 36675367 PMC: 9862106. DOI: 10.3390/jcm12020438.

Inhibition of NADPH Oxidase-ROS Signal using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy.

Zhu L, Zhao Y, Liu T, Chen M, Qian W, Jiang B ACS Nano. 2022; 16(11):18708-18728.

PMID: 36256454 PMC: 9764083. DOI: 10.1021/acsnano.2c07440.

The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Gallez B Front Pharmacol. 2022; 13:853568.

PMID: 35910347 PMC: 9335493. DOI: 10.3389/fphar.2022.853568.

References

Wouters B, Delahoussaye Y, Evans J, Birrell G, Dorie M, Wang J . Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res. 2001; 61(1):145-52. View

Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y . Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res. 2012; 72(17):4318-28. PMC: 3609716. DOI: 10.1158/0008-5472.CAN-12-0056. View

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

Brown J, Wilke L, Geradts J, Kennedy S, Palmer G, Ramanujam N . Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo. Cancer Res. 2009; 69(7):2919-26. PMC: 2677720. DOI: 10.1158/0008-5472.CAN-08-3370. View

Snyder S, Lanzen J, Braun R, Rosner G, Secomb T, Biaglow J . Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone. Int J Radiat Oncol Biol Phys. 2001; 51(2):494-506. DOI: 10.1016/s0360-3016(01)01654-6. View

Secomb T, Hsu R, Ong E, Gross J, Dewhirst M . Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 1995; 34(3):313-6. DOI: 10.3109/02841869509093981. View

Secomb T, Hsu R, Braun R, Ross J, Gross J, Dewhirst M . Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol. 1999; 454:629-34. DOI: 10.1007/978-1-4615-4863-8_74. View

Moon E, Brizel D, Chi J, Dewhirst M . The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal. 2007; 9(8):1237-94. DOI: 10.1089/ars.2007.1623. View

Wardman P . Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 2007; 19(6):397-417. DOI: 10.1016/j.clon.2007.03.010. View

10.

Benej M, Hong X, Vibhute S, Scott S, Wu J, Graves E . Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A. 2018; 115(42):10756-10761. PMC: 6196495. DOI: 10.1073/pnas.1808945115. View

11.

Rischin D, Hicks R, Fisher R, Binns D, Corry J, Porceddu S . Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation.... J Clin Oncol. 2006; 24(13):2098-104. DOI: 10.1200/JCO.2005.05.2878. View

12.

Overgaard , Horsman . Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. Semin Radiat Oncol. 1996; 6(1):10-21. DOI: 10.1053/SRAO0060010. View

13.

Horsman M, Mortensen L, Petersen J, Busk M, Overgaard J . Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012; 9(12):674-87. DOI: 10.1038/nrclinonc.2012.171. View

14.

Hunter F, Wouters B, Wilson W . Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br J Cancer. 2016; 114(10):1071-7. PMC: 4865974. DOI: 10.1038/bjc.2016.79. View

15.

THOMLINSON R, GRAY L . The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9(4):539-49. PMC: 2073776. DOI: 10.1038/bjc.1955.55. View

16.

Coleman C, Bump E, Kramer R . Chemical modifiers of cancer treatment. J Clin Oncol. 1988; 6(4):709-33. DOI: 10.1200/JCO.1988.6.4.709. View

17.

Ghatage P, Sabagh H . Is there a role for tirapazamine in the treatment of cervical cancer?. Expert Opin Drug Metab Toxicol. 2012; 8(12):1589-97. DOI: 10.1517/17425255.2012.730518. View

18.

Overgaard J . Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol. 2011; 100(1):22-32. DOI: 10.1016/j.radonc.2011.03.004. View

19.

Wang J, Foehrenbacher A, Su J, Patel R, Hay M, Hicks K . The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res. 2011; 18(6):1684-95. DOI: 10.1158/1078-0432.CCR-11-2296. View

20.

Rischin D, Peters L, OSullivan B, Giralt J, Fisher R, Yuen K . Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010; 28(18):2989-95. DOI: 10.1200/JCO.2009.27.4449. View